Scientific article

Revisiting IL-6 antagonism in multiple myeloma

Published inCritical reviews in oncology/hematology, vol. 105, p. 1-4
Publication date2016

IL-6, a cytokine with broad functions in inflammation and immunity, has been extensively studied for its role on normal antibody-producing plasma cells. In addition, IL-6 is recognized as a proliferative factor for multiple myeloma (MM), a malignant plasma cell tumor developing in the bone marrow. Blocking IL-6 signaling was thus developed into a therapeutic approach for MM already early after its discovery, in 1991. Unfortunately, the first clinical trials did not demonstrate a clear benefit, but despite this apparent failure hopes on IL-6 antagonism are still high and trials ongoing. The cellular source of IL-6 has long been a matter of debate. IL-6 was first recognized as an autocrine factor produced by the malignant plasma cells themselves, but later reports clearly showed that IL-6 was a paracrine factor, produced by the microenvironment, mostly by cells from the myeloid lineage. Recently, we have confirmed that IL-6 originates from myeloid lineage cells, mainly from myeloid precursors. We have also demonstrated that IL-6 amplifies the pool of myeloid cells producing a second key factor for MM, a proliferation inducing ligand (APRIL). These findings form a new rationale for IL-6 inhibition in MM and for new ways to use IL-6 blocking in the clinics.

Citation (ISO format)
MATTHES, Thomas, MANFROI, Benoit, HUARD, Bertrand. Revisiting IL-6 antagonism in multiple myeloma. In: Critical reviews in oncology/hematology, 2016, vol. 105, p. 1–4. doi: 10.1016/j.critrevonc.2016.07.006
Main files (1)
Article (Published version)
ISSN of the journal1040-8428

Technical informations

Creation10/26/2016 9:13:00 AM
First validation10/26/2016 9:13:00 AM
Update time03/15/2023 12:56:07 AM
Status update03/15/2023 12:56:06 AM
Last indexation08/30/2023 12:18:41 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack